(Total Views: 418)
Posted On: 06/26/2021 10:00:54 PM
Post# of 653
$RLFTF $NRXP DD (opinion) by WONG on Yh0 - Seeing the stark difference between tertiary hospitals and regional hospitals we now have our answer as to why Aviptadil was selected for the ACTIV-3b trial.
The NIH wants to see how well Aviptadil works in a controlled setting. It is basically a continuation of our trial with real time data streaming in.
This proves that they believe it is safe and MAY be effective. By putting Aviptadil in this trial and allowing the EAP to continue is all I need to know to feel confident that an EUA will be issued. Hold or load.
The NIH wants to see how well Aviptadil works in a controlled setting. It is basically a continuation of our trial with real time data streaming in.
This proves that they believe it is safe and MAY be effective. By putting Aviptadil in this trial and allowing the EAP to continue is all I need to know to feel confident that an EUA will be issued. Hold or load.
(0)
(0)
$MJ
